Full-Time

District Sales Manager

Endoscopy

Posted on 7/8/2026

Deadline 7/17/26
Medtronic

Medtronic

10,001+ employees

Medical device maker advancing therapies

Compensation Overview

$142k/yr

+ Long-Term Incentive Plan + Sales Incentive Plan (SIP)

No H1B Sponsorship

Texas, USA

Remote

Must reside in Texas; remote role with regional travel to accounts.

Bachelor's, Master's, PhD

Category
Sales & Account Management (1)
Required Skills
Sales
Forecasting
Salesforce
Data Analysis

Get referred to Medtronic

See people who can refer or advise you

Requirements
  • Bachelor’s degree required
  • Minimum of 5 years of relevant sales and leadership experience (direct or indirect) or advanced degree with a minimum of 3 years of relevant sales and leadership experience (direct or indirect)
Responsibilities
  • Achieve monthly, quarterly and annual region sales quotas.
  • Drive Endoscopy commercial sales strategy, process and methodologies across region.
  • Conduct 2-3 days of field rides with each Territory Manager at least once each quarter to observe performance in all sites of care including hospitals, physician offices and clinics.
  • Provide written field coaching reports to each Territory Manager following observed time in territory.
  • Weekly reviews with Territory Manager to evaluate performance and ensure compliance with KPIs.
  • Implement Medtronic’s Performance and Career Development framework with their Territory Managers to ensure continued personal development and achievement of career goals.
  • Create a high-performance environment within the Region that leads to sustainable success.
  • Develop and lead market development initiatives in collaboration with commercial market development team to launch Endoscopy products throughout region.
  • Create actionable sales plans and develop quarterly forecasts through the utilization of Salesforce.com.
  • Collaborate with cross-functional counterparts including remote sales, commercial market development, marketing and clinical support teams by consistently communicating and sharing best practices.
  • Function as an integral member of the Endoscopy Sales Management team.
  • Establish relationships with key opinion leaders and IDN partners in the Region.
  • Develop understanding and ability to communicate the reimbursement process for our products.
  • Responsible for continuing education to understand and be able to communicate clinical and product knowledge of the entire Endoscopy product portfolio and general Gastrointestinal disease state knowledge.
  • Consistently perform administrative responsibilities, such as expense reports, sales reports, and other business requests.
  • Develop quarterly region business plans and effectively communicate them to their teams as well as senior management.
  • Attend internal sales leadership meetings and plan and coordinate region level sales meetings.
  • Demonstrate proficiency by completing online trainings within assigned timelines.
  • Utilize Salesforce for data entry, analysis, forecasting and sales planning.
  • Adhere to the Medtronic Code of Conduct.
Desired Qualifications
  • Sales management experience highly preferred, within the medical device industry
  • 2+ years of GI/Ablation experience preferred.
  • Proven track record of exceeding sales quotas.
  • Established business planning and forecasting experience.
  • Demonstrated formal sales skills training, preferably from a Fortune 500 company.
  • Good computer skills with specific skills in Microsoft Office: Power Point, Excel and Word.
  • Medical device/equipment sales experience
  • Experience with the Capital Sales Process
  • Experience leading through organizational change
  • Ability to establish and maintain good working relationships with all functional areas
  • Strong problem-solving skills
  • Ability to coach and teach others
  • Ability to multi-task and work independently
  • Experience presenting reimbursement related medical device sales
  • Strong written and oral communication skills
  • For Baccalaureate degrees earned outside of the United States, a degree that satisfies the requirements of 8 C.F.R. § 214.2(h)(4)(iii)(A) is required.

Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Fridley, Minnesota

Founded

1949

Get referred to Medtronic

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Canada approved Affera in August 2026, expanding commercial reach beyond the United States.
  • Medtronic’s fiscal 2026 revenue reached $36.4 billion, its strongest annual growth in a decade.
  • CoreMap’s July 31, 2026 Series C, led by Medtronic, strengthens its AF mapping ecosystem.

What critics are saying

  • August 4, 2026’s $88 million Covidien mesh verdict expands thousands of pending hernia claims.
  • MiniMed’s March 2026 IPO raised only $560 million, below pricing expectations, signaling weak demand.
  • Boston Scientific and Abbott pressure Medtronic in ablation; execution slips in 2027 would erase share gains.

What makes Medtronic unique

  • Medtronic’s Affera and PulseSelect platforms give it two pulsed-field ablation franchises.
  • MiniMed’s March 2026 IPO preserved diabetes optionality while letting Medtronic refocus on higher-margin categories.
  • The company’s 78% fiscal Q4 2026 Cardiac Ablation Solutions growth proves scale in electrophysiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

1%
Yahoo Finance
Aug 16th, 2026
Medtronic faces $88M hernia mesh verdict as Health Canada approves cardiac ablation system

Medtronic faces contrasting developments after a federal jury ordered it to pay $88 million in compensatory damages over injuries linked to Covidien hernia mesh in August 2026. The verdict represents a record settlement in the ongoing litigation. Meanwhile, Medtronic Canada secured Health Canada approval for its Affera Integrated Mapping and Ablation System, designed to treat atrial fibrillation and atrial flutter. The approval gives Medtronic a second pulsed field ablation platform alongside its existing PulseSelect system. The company's investment narrative projects $41.5 billion in revenue and $6.6 billion in earnings by 2029, requiring 4.5% annual revenue growth. Analysts estimate a fair value of $98.00, representing a 7% upside from current levels. However, cautious analysts forecast lower revenue of around $38.6 billion and earnings of approximately $6.2 billion by 2029, citing concerns over legal exposure and execution risks.

Yahoo Finance
Aug 16th, 2026
Medtronic wins Health Canada approval for Affera heart rhythm system

Medtronic has received Health Canada approval for its Affera Integrated Mapping System and Sphere-9 Catheter to treat atrial fibrillation and atrial flutter. The licence permits commercial use of Medtronic's combined pulse field and radiofrequency ablation technologies across Canada. The Affera system offers physicians an all-in-one mapping and ablation platform designed to support procedural efficiency and patient care. The approval represents a milestone for Medtronic's Cardiac Ablation Solutions division in the global atrial fibrillation treatment market. Medtronic, a US-based medical equipment company with a market capitalisation of approximately $115.9 billion, develops and sells device-based therapies to healthcare systems and clinicians globally. The approval extends Medtronic's cardiac ablation offerings from Europe and the US into Canada, where it will compete with Abbott and Boston Scientific.

BIBA Medical
Aug 13th, 2026
Medtronic executive Shields appointed CEO at Versa Vascular.

Medtronic executive Shields appointed CEO at Versa Vascular. 13th August 2026 Versa Vascular, developer of a novel transcatheter tricuspid valve repair system - AdapTR - has announced changes to its senior management team and the completion of new investment to support clinical study of its device. The company announced that Bill Shields, a former vice president and general manager of Medtronic's Transcatheter Mitral and Tricuspid Therapies division joins as CEO, replacing the retiring David Hovda, who will remain as an advisor to the company. According to Versa, Shields spent 15 years with Medtronic, where he spent seven years leading product development and multiple clinical studies. Previously, he led upstream and downstream marketing for the company's transcatheter valve programs over eight years, including multiple successful product launches. The company also announced a US$15 million expansion to its series C financing, bringing the total committed capital for the round to US$42 million, supporting completion of the ongoing first-in-human clinical study of the AdapTR device outside of the USA, a US early feasibility study of the technology, and further product development and optimisation. "I am thrilled to join Versa Vascular at a time when we are seeing positive results clinically, close to expanding our clinical work to the USA, and receiving continued investor confidence," said Shields. "I have seen and launched a number of innovative transcatheter devices in my career, and the AdapTR technology shows similar promise to create a superior therapy for patients. I want to thank David Hovda and the team for their commitment to product development and refinement that has led to a truly novel solution that is showing it can have a positive impact on patients' lives." "We strongly believe in Versa's vision to improve the lives of patients with tricuspid disease, and we are proud to continue supporting the company as it executes on its clinical milestones," said Brian R Smith, founder and managing director of S3 Ventures. "We also enthusiastically welcome Bill Shields to the Versa team," said Louis A Cannon, founder of BioStar Capital. "Bill's deep structural heart expertise, experience developing new transcatheter therapies, scaling up operations, and strong industry connections align closely with BioStar's mission to improve patients' lives."

Yahoo Finance
Aug 9th, 2026
UBS upgrades Medtronic to Buy as cardiac segment drives 78% revenue growth

UBS upgraded Medtronic to Buy from Neutral, citing an ongoing turnaround at the medical technology company. The upgrade follows Medtronic's strongest annual revenue growth in a decade, with Q4 revenue reaching $9.8 billion, up 6.6% organically, and full-year revenue hitting $36.4 billion, up 5.8% organically. The company's cardiac segment showed particularly strong growth, with Cardiac Ablation Solutions revenue rising 78% globally. New product launches, including Symplicity Spyral for hypertension, which is now annualising at $100 million, are gaining traction. However, analysts caution that several more quarters of consistent execution are needed before the turnaround can be considered complete, given management's multi-year efforts to accelerate growth.

Yahoo Finance
Aug 8th, 2026
Medtronic and Intuitive Surgical lag market amid sector weakness

Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.

INACTIVE